Analyzed secondary indicia of non-obviousness involving Hatch-Waxman litigation related to a Paragraph IV certification by a generic drug producer alleging that the patented invention was obvious and that the patent was invalid. Specific secondary indicia considered related to the commercial success of the product that embodied the patented features and evidence of long-felt need in the market and the failure of others to address it.